Meridian Bioscience

Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Our products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections.
In addition, we develop and manufacture a variety of biological and non-biological materials used in proficiency testing programs.

Type
Public
HQ
Cincinnati, US
Founded
1977
Size (employees)
650 (est)+13%
Meridian Bioscience was founded in 1977 and is headquartered in Cincinnati, US

Meridian Bioscience Office Locations

Meridian Bioscience has an office in Cincinnati
Cincinnati, US (HQ)
3471 River Hills Dr

Meridian Bioscience Data and Metrics

Meridian Bioscience Financial Metrics

Meridian Bioscience's revenue was reported to be $54.1 m in Q2, 2017
USD

Revenue (Q2, 2017)

54.1 m

Gross profit (Q2, 2017)

33.5 m

Gross profit margin (Q2, 2017), %

62%

Net income (Q2, 2017)

9.3 m

EBIT (Q2, 2017)

14.2 m

Market capitalization (21-Jul-2017)

653.4 m

Cash (31-Mar-2017)

54.7 m
Meridian Bioscience's current market capitalization is $653.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

188.7 m188.8 m194.8 m196.1 m

Revenue growth, %

0%3%1%

Cost of goods sold

67.6 m71.6 m72.9 m68.3 m

Gross profit

121 m117.2 m121.9 m127.8 m

Gross profit Margin, %

64%62%63%65%

Operating expense total

63.7 m64.9 m65.8 m76.4 m

EBIT

57.3 m52.4 m56.1 m51.4 m

EBIT margin, %

30%28%29%26%

Interest expense

897 k

Interest income

44 k25 k23 k67 k

Pre tax profit

57.4 m52.1 m55.1 m50.6 m

Income tax expense

19.3 m17.4 m19.5 m18.4 m

Net Income

38 m34.7 m35.5 m32.2 m
USDQ3, 2014Q1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017

Revenue

47.2 m48 m51.5 m48.2 m47.2 m51.3 m50.7 m46.8 m54.1 m

Cost of goods sold

18 m18.8 m19 m17.9 m15.6 m17.7 m17.8 m17.4 m20.6 m

Gross profit

29.2 m29.2 m32.5 m30.3 m31.6 m33.6 m32.9 m29.5 m33.5 m

Gross profit Margin, %

62%61%63%63%67%65%65%63%62%

R&D expense

3.1 m3.1 m3.4 m3.2 m3.4 m3.1 m3.5 m3.4 m3.9 m

General and administrative expense

6.7 m7.4 m6.9 m6.5 m8.2 m6.9 m7.5 m8.4 m7.4 m

Operating expense total

9.9 m10.5 m10.3 m9.7 m11.6 m10 m11.1 m11.9 m11.3 m

EBIT

13.1 m12.7 m15.7 m14.4 m13.6 m15.2 m13.7 m10.1 m14.2 m

EBIT margin, %

28%26%31%30%29%30%27%22%26%

Interest expense

(43 k)(427 k)(423 k)(408 k)

Interest income

5 k6 k6 k6 k17 k3 k22 k22 k29 k

Pre tax profit

12.9 m12.1 m15.5 m14.3 m13.7 m14.8 m13.4 m9.7 m14.2 m

Income tax expense

4 m4.2 m5.5 m5.2 m4.8 m5.7 m4.6 m3.4 m4.9 m

Net Income

8.8 m7.9 m10.1 m9.1 m8.9 m9.1 m8.8 m6.3 m9.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.3 m43 m50 m47.2 m

Inventories

34.8 m35.5 m35.8 m45.1 m

Current Assets

114.1 m112.7 m122.9 m126.8 m

Goodwill

23.1 m23.2 m22.3 m62 m

Total Assets

176.7 m176.9 m183.3 m251.8 m

Accounts Payable

5.6 m5 m6.6 m7.6 m

Total Debt

58.4 m

Current Liabilities

21.7 m13.7 m15.3 m22.6 m

Non-Current Liabilities

2.2 m2.2 m62.8 m

Total Liabilities

15.9 m17.4 m85.4 m

Additional Paid-in Capital

107.4 m111.9 m117.2 m122.4 m

Retained Earnings

46.9 m48.9 m51.1 m49.6 m

Total Equity

155 m161 m165.9 m166.5 m

Debt to Equity Ratio

0.4 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.5 x
USDQ3, 2014Q1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017

Cash

39.3 m49.5 m42.7 m46 m53.4 m48.9 m45.8 m49.3 m54.7 m

Inventories

37.6 m34.4 m33 m33.6 m38.8 m41.9 m43.4 m44.7 m42.4 m

Current Assets

113.5 m114.7 m116.5 m118 m123.2 m128.2 m126.9 m126 m128.8 m

Goodwill

23.8 m22.6 m22.1 m22.8 m22.1 m64.5 m63.7 m60.7 m60.8 m

Total Assets

178.8 m177.4 m178.3 m179.3 m186.4 m258.4 m254.9 m250.1 m251.9 m

Accounts Payable

6.4 m5.9 m6.1 m5.5 m7.2 m7.9 m7.4 m7.5 m6.4 m

Current Liabilities

16.9 m14.5 m15.2 m13.3 m15.7 m21.3 m20.2 m21 m19.9 m

Non-Current Liabilities

2 m2 m2.1 m2.1 m67.2 m65.8 m63.3 m61.2 m

Additional Paid-in Capital

110.7 m113.5 m114.1 m114.8 m120.2 m121.3 m121.7 m124.2 m124.7 m

Retained Earnings

49 m48.4 m50.2 m50.9 m51.5 m52.2 m52.6 m47.5 m51.5 m

Total Equity

161.8 m160.8 m161.1 m163.9 m168.6 m169.8 m168.9 m165.7 m170.8 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.5 x1.5 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

38 m34.7 m35.5 m32.2 m

Cash From Operating Activities

44.4 m38.3 m42.8 m37.2 m

Purchases of PP&E

(3.2 m)(5.3 m)(4.6 m)(4 m)

Cash From Investing Activities

(3.3 m)(7 m)(3.6 m)(66.7 m)

Dividends Paid

(31.4 m)(32.8 m)(33.4 m)(33.6 m)

Cash From Financing Activities

(28.6 m)(31.8 m)(30.7 m)27.2 m

Interest Paid

879 k

Income Taxes Paid

20.1 m20 m20.2 m17.9 m
USDQ3, 2014Q1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017

Net Income

8.8 m7.9 m10.1 m9.1 m8.9 m9.1 m8.8 m6.3 m9.3 m

Inventories

33.6 m38.8 m41.9 m43.4 m44.7 m42.4 m

Accounts Payable

5.5 m7.2 m7.9 m7.4 m7.5 m6.4 m
USDY, 2017

Revenue/Employee

83.3 k

Financial Leverage

1.5 x

Meridian Bioscience Market Value History

Meridian Bioscience Online and Social Media Presence

Meridian Bioscience Company Life and Culture

You may also be interested in